Cullinan Therapeutics Inc.

CGEM | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.35

+$0.27 (+1.28%)

At close: Sep 21, 2026, 4:00 PM ET

$21.96

+$0.61 (+2.86%)

Pre-market: Sep 22, 2026, 9:11 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.31B

Enterprise Value $979.66M

Beta -0.01

Average Volume 934.37K

Shares Outstanding (Diluted) 61.49M

Shares Change YoY 4.2%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US2300311063

Price Performance

Price Change 1M -1.3%

Price Change 3M 20.3%

Price Change 6M 51.9%

Price Change YTD 111.0%

Price Change 1Y 240.0%

Price Change 3Y 125.0%

Price Change 5Y -7.4%

1M CAGR (ann.) 20.4%

1Y CAGR (ann.) 236.8%

5Y CAGR (ann.) -5.9%

All-Time CAGR -5.7%

Valuation

PE Ratio -6.34

Forward PE N/A

PEG Ratio -2.02

Forward PEG 0.35

PS Ratio N/A

Forward PS 27.40

PB Ratio 4.08

P/FCF Ratio -6.39

P/Adj. FCF Ratio -5.34

P/OCF Ratio -8.24

EV/Sales N/A

EV/EBIT -4.69

EV/EBITDA -4.70

EV/FCF -4.77

Earnings Yield -15.8%

FCF Yield -15.7%

Adj. FCF Yield -18.7%

Financial Health

Net Cash $333.13M

Total Debt $2.07M

Cash & Short-Term Investments $334.54M

Total Assets $363.79M

Current Ratio 8.42

Quick Ratio 8.42

Debt / Equity Ratio 0.01

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -99.13

Interest Coverage 0.00

Altman Z-Score 15.17

Piotroski F-Score 1

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -19.7%

Returns

Return on Assets -56.3%

Return on Equity -52.9%

Return on Invested Capital -68.5%

Return on Capital Employed -68.6%

Return on Tangible Assets -56.3%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y -100.0%

Revenue CAGR 10Y N/A

EPS CAGR 3Y -4.0%

EPS CAGR 5Y -52.9%

EPS CAGR 10Y N/A

FCF CAGR 3Y -23.4%

FCF CAGR 5Y -18.5%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 8

EPS Growth Next 3Y 4.1%

Revenue Growth Next 3Y N/A

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$0.84

EPS Growth Est (next Q) 9.7%

Revenue Est (next Q) $2M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $33.50

Price Target Upside 56.9%

Cash Flow

Operating Cash Flow $-205.3M

Free Cash Flow $-205.34M

Adj. Free Cash Flow $-245.8M

FCF Per Share -$2.59

OCF Per Share -$2.59

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-221.81M

EBITDA $-208.41M

Net Income $-204.69M

EPS (Diluted) -$3.37

Revenue / Employee N/A

Profit / Employee $-1.88M

Employees 109